Yanbing Zhou

Dr. Yanbing Zhou

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2016 in Oncotarget
Verified
Journal Article
Open access
ZWZhiliang Wei
Zhiliang Wei
SCShougen Cao
Shougen Cao
SLShanglong Liu
Shanglong Liu
ZYZengwu Yao
Zengwu Yao
TSTeng Sun
Teng Sun
YZYanbing Zhou
Yanbing Zhou
Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients survival? A pilot study on relevant mechanism

1 February 2021 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
XZXin Zhou
Xin Zhou
SCShou-Gen Cao
Shou-Gen Cao
XTXiao-Jie Tan
Xiao-Jie Tan
XLXiao-Dong Liu
Xiao-Dong Liu
ZLZe-Qun Li
Ze-Qun Li
YZYanbing Zhou
Yanbing Zhou
Purpose: Transcutaneous electrical acupoint stimulation (TEAS) is an innovative choice for postoperative pain management. However, the safety and effectiveness of this traditional Chinese medicine (TCM) therapy for patients who underwent gastrectomy is largely unknown. So, the purpose of this study is to evaluate the safety and effectiveness of TEAS for patients who underwent gastrectomy. Patients and Methods: We recruited 96 patients with gastric cancer from May 2019 to November 2019; 82 patients were enrolled, and 81 patients completed. Patients were randomly assigned to TEAS group (TG) received TEAS on postoperative day (POD) 1– 3 or control group (CG) at a 1:1 ratio. The primary outcomes were pain score and consumption of analgesics. The secondary were the time of first postoperative flatus and defecation, frequency of postoperative nausea, vomiting, distention, diarrhea, comfort of semi-fluid diet, Clavien-Dindo grade (C-D grade) and length of postoperative day. We performed hematological analysis to explore the possible mechanisms. Results: Overall, 81 patients were enrolled included in the analysis. Compared with CG, pain scores in TG were lower on POD 1– 5 (average: 2.55± 0.21 vs 3.10± 0.42, P< 0.001), and the use rate of opioids was lower (43.9 vs 75.0, P=0.004); time of first postoperative flatus (55.63± 16.74 vs 72.60± 20.92, P< 0.001) and defecation (72.20± 16.24 vs 95.78± 17.75, P< 0.001) were shorter; the frequency of nausea were fewer (1.88± 1.09 vs 2.58± 0.77, P=0.029) and patients were more comfortable with semi-fluid diet (7.63± 0.63 vs 6.93± 0.69, P< 0.001); among the hematologic results, β-endorphin (β-End), interleukin-2 (IL-2), motilin (MTL) on POD 3, POD 5 were lower, 5-hydroxytryptamine (5-HT), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) were higher. And no adverse event was reported. Conclusion: TEAS can relieve postoperative pain and promote the recovery of gastrointestinal function. Consequently, it can be an adjunctive therapy to enhance postoperative recovery for patients after gastrectomy.

7 April 2021 in Annals of Surgery
Verified
Journal Article
Open access
YTYulong Tian
Yulong Tian
SCShougen Cao
Shougen Cao
XLXiaodong Liu
Xiaodong Liu
LLLeping Li
Leping Li
QHQingsi He
Qingsi He
YZYanbing Zhou
Yanbing Zhou
Objective: This study aimed to compare the effects of ERAS and conventional programs on short-term outcomes after LDG. Summary of Background Data: Currently, the ERAS program is broadly applied in surgical areas. Although several benefits of LDG with the ERAS program have been covered, high-level evidence is still limited, specifically in advanced gastric cancer. Methods: The present study was designed as a randomized, multicenter, unblinded trial. The enrollment criteria included histologically confirmed cT2-4aN0-3M0 gastric adenocarcinoma. Postoperative complications, mortality, readmission, medical costs, recovery, and laboratory outcomes were compared between the ERAS and conventional groups. Results: Between April 2019 and May 2020, 400 consecutive patients who met the enrollment criteria were enrolled. They were randomly allocated to either the ERAS group (n = 200) or the conventional group (n = 200). After excluding patients who did not undergo surgery or gastrectomy, 370 patients were analyzed. The patient demographic characteristics were not different between the 2 groups. The conventional group had a significantly longer allowed day of discharge and postoperative hospital stay (6.96 vs 5.83 days, P < 0.001; 8.85 vs 7.27 days, P < 0.001); a longer time to first flatus, liquid intake and ambulation (3.37 vs 2.52 days, P < 0.001; 3.09 vs 1.13 days, P < 0.001; 2.85 vs 1.38 days, P < 0.001, respectively); and higher medical costs (6826 vs 6328 $, P = 0.027) than the ERAS group. Additionally, patients in the ERAS group were more likely to initiate adjuvant chemotherapy earlier (29 vs 32 days, P = 0.035). There was no significant difference in postoperative complications or in the mortality or readmission rates. Regarding laboratory outcomes, the procalcitonin and C-reactive protein levels on postoperative day 3 were significantly lower and the hemoglobin levels on postoperative day 5 were significantly higher in the ERAS group than in the conventional group. Conclusion: The ERAS program provides a faster recovery, a shorter postoperative hospitalization length, and lower medical costs after LDG without increasing complication and readmission rates. Moreover, enhanced recovery in the ERAS group enables early initiation of adjuvant chemotherapy.

18 November 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
TSTeng Sun
Teng Sun
SLShanglong Liu
Shanglong Liu
YZYanbing Zhou
Yanbing Zhou
ZYZengwu Yao
Zengwu Yao
DZDongfeng Zhang
Dongfeng Zhang
SWSong Wang
Song Wang
Oncotarget | https://doi.org/10.18632/oncotarget.13443 Teng Sun, Shanglong Liu, Yanbing Zhou, Zengwu Yao, Dongfeng Zhang, Shougen Cao, Zhiliang Wei, Bin Tan, Yi Li, Zheng Lian, Song Wang Evolutionary biologic changes of gut microbiota in an ‘adenoma–carcinoma sequence’ mouse colorectal cancer model induced by 1, 2-Dimethylhydrazine

6 September 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
HLHongda Liu
Hongda Liu
ZLZequn Li
Zequn Li
QZQun Zhang
Qun Zhang
QLQingya Li
Qingya Li
HZHao Zhong
Hao Zhong
ZXZekuan Xu
Zekuan Xu
Background: Early-onset gastric cancer (EOGC, ≤45 years old) is characterized with increasing incidence and more malignant phenotypes compared with late-onset gastric cancer, which exhibits remarkable immune cell infiltration and is potential immunotherapeutic population. Till now, restricted survival information of EOGC is available due to limited case numbers. This study established a novel nomogram to help evaluate cancer-specific survival (CSS) of EOGC patients who underwent gastrectomy, and may provide evidence for predicting patients’ survival.Methods: We retrospectively enrolled a cohort containing 555 EOGC cases from five independent medical centers in China, among which 388 cases were randomly selected into a training set while the other 167 cases were assigned into the internal validation set. Asian or Pacific Islander (API) patients diagnosed with EOGC during 1975-2016 were retrieved from the SEER database (n=299) and utilized as the external validation cohort. Univariate and multivariate analyses were conducted to test prognostic significances of clinicopathological factors in the training set. Accordingly, two survival nomogram models were established and compared by concordance index (C-index), calibration curve, receiver operating characteristics (ROC) curves and decision curve analyses (DCA).Results: The 5-year CSS rate of training cohort was 61.3% with a median survival time as 97.2 months. High consistency was observed on calibration curves in all three cohorts. Preferred nomogram was selected due to its better performance on ROC and DCA results. Accordingly, a novel predicative risk model was introduced to better stratify high-risk EOGC patients with low-risk patients. In brief, the 5-year CSS rates for low-risk groups were 92.9% in training set, 83.1% in internal validation set, 89.9% in combined NQSQS cohort, and 85.3% in SEER-API cohort. In contrast, the 5-year CSS rates decreased to 38.5%, 44.3%, 40.5%, and 36.9% in the high-risk groups of the four cohorts above, respectively. The significant survival difference between high-risk group (HRG) and low-risk group (LRG) indicated the precise accuracy of our risk model. Furthermore, the risk model was validated in patients with different TNM stages, respectively. Finally, an EOGC web-based survival calculator was established with public access, which can help predict prognosis.Conclusions: Our data provided a precise nomogram on predicting CSS of EOGC patients with potential clinical applicability.

11 January 2021 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
YTYulong Tian
Yulong Tian
SCShougen Cao
Shougen Cao
YKYing Kong
Ying Kong
SSShuai Shen
Shuai Shen
ZNZhaojian Niu
Zhaojian Niu
YZYanbing Zhou
Yanbing Zhou